Ionis Pharmaceuticals, Inc. IONS
30.31 USD -9.11 (-23.11%)
Nov 9, 2026, 2:18 PM EST
27.75 Day range 32.58
30.39 52-week range 86.50
- YTD
- -61.69%
- 1 year
- -58.79%
News
benzinga.com Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday? Ionis Pharmaceuticals stock hits a 52-week low after halving 2026 Tryngolza guidance, despite beating Q3 earnings estimates and posting 55% revenue growth.
benzinga.com Nasdaq 100 Jumps 3% as Chips Rebound; Nvidia Lags Most Since DeepSeek: Stock Market Today Wall Street rebounds from last week's rout as SOXX jumps 7%, while Nvidia slides on a CEO probe for its worst day versus the S&P 500 since DeepSeek.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com Ionis Pharmaceuticals Q3 Adj. EPS $(0.40) Beats $(1.21) Estimate, Sales $243.000M Beat $182.117M Estimate Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(1.21) by 66.94 percent. This is a 34.43 percent increase over losses…
benzinga.com Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $916.396M Est Ionis Pharmaceuticals (NASDAQ:IONS) affirms FY2026 sales outlook from $875.000 million-$900.000 million to $875.000 million-$900.000 million vs $916.396 million estimate.
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
businesswire.com Ionis to hold third quarter 2026 financial results webcast CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Monday, November 9 at 9:00 a.m. Eastern Time to discuss its third…
benzinga.com This CME Group Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday Analysts upgraded Ionis, CME Group, DigitalOcean, Prologis and Zions Bancorporation, issuing new or revised price targets.
benzinga.com BMO Capital Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $66 BMO Capital analyst David Lebowitz upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and raises the price target from $54 to $66.- benzinga.com Ionis Pharmaceuticals Receives EMA CHMP Positive Opinion Recommending Indication Extension For TRYNGOLZA For Treatment Of Adult Patients With Severe Hypertriglyceridemia Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion…
benzinga.com HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $100 price target.
benzinga.com Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease Ionis and Roche report positive Phase 3 IMAgINATION trial interim results for sefaxersen in treating primary IgA nephropathy.
benzinga.com Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks – Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential –– IgAN is a progressive kidney…
benzinga.com Ionis to Seek Expedited FDA Review for ALS Drug Ionis Pharmaceuticals and Otsuka Pharmaceutical report positive Phase 3 data for ulefnersen, an investigational RNA-targeted drug for ALS.
benzinga.com Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.- benzinga.com JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70 JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $76 to $70.
- benzinga.com Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80 Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $89 to $80.
- benzinga.com Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85 Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $90 to $85.
- benzinga.com Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $104 Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $110 to $104.
benzinga.com Why Is Eli Lilly Stock Falling Tuesday? Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.
benzinga.com Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $56 Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $69 to $56.
benzinga.com Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.
benzinga.com BMO Capital Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $54 BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and lowers the price target from $61 to $54.
benzinga.com Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
benzinga.com Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.- benzinga.com Canaccord Genuity Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $85 Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $95 to $85.
- benzinga.com HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $100 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $115 to $100.
benzinga.com Market-Moving News for September 8th NVS: -13% | Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint. IONS: -13% | Ionis Pharmaceuticals shares are…- benzinga.com Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint; Lowered Lp(a) Levels But Did Not Reduce CV Events Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events,…
- benzinga.com Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $86 Price Target Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $86 price target.
- benzinga.com BMO Capital Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $61 BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and raises the price target from $60 to $61.
benzinga.com Ionis Drug Wins FDA Approval as First Alexander Disease Treatment FDA approves Zanvastro from Ionis Pharmaceuticals as the first disease-modifying treatment for rare Alexander disease.- benzinga.com HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $115 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $115 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $115 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $115 price target.
benzinga.com This Allstate Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday Wall Street analysts changed outlook on top names. Check all rating changes, including upgrades/downgrades, on Benzinga analyst ratings page.
benzinga.com This Merck Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Wall Street analysts upgraded PGR, MRK, EPR and initiated coverage on BEKE and IONS. Check analyst ratings and price targets for these stocks.
benzinga.com This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Top Wall Street analysts updated ratings on SPHR, CVLG, MIST, MSGE,. Check out analyst ratings page for full details and stock recommendations.
benzinga.com This Baidu Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and price targets on Benzinga's analyst page.
benzinga.com This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.- benzinga.com BMO Capital Initiates Coverage On Ionis Pharmaceuticals with Market Perform Rating, Announces Price Target of $60 BMO Capital analyst David Lebowitz initiates coverage on Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform rating and announces Price Target of $60.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $76 JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and raises the price target from $72 to $76.
benzinga.com Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighed on expectations and investors reacted.- benzinga.com Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $95 Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $100 to $95.
benzinga.com Microsoft To Rally More Than 40%? Here Are 10 Top Analyst Forecasts For Thursday Wall Street analysts changed outlook on top names: Barclays cut META price target, Needham boosted QTWO target, Deutsche Bank upgraded GTX & more.
benzinga.com HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $115 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $125 to $115.
benzinga.com Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pipeline progress.- benzinga.com Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $895.148M Est Ionis Pharmaceuticals (NASDAQ:IONS) affirms FY2026 sales outlook from $875.000 million-$900.000 million to $875.000 million-$900.000 million vs $895.148 million estimate.
- benzinga.com Ionis Pharmaceuticals Q2 Adj. EPS $(0.42) Beats $(1.07) Estimate, Sales $268.000M Beat $190.670M Estimate Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(1.07) by 60.75 percent. This is a 149.41 percent decrease over…
- benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…